Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

VAXART, INC. VXRT

Healthcare — Biotechnology
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.03
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 2 — — — — — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership
6.29%

Capital & Financial Ratios

Market Cap
92.41
Revenue
243.06
Net Income
38.59
Free Cash Flow
33.40
Net Debt
(63.98)
Current Ratio
1.60
Debt/Equity
0.00
P/E ratio
3.13
P/S ratio
0.50
P/B ratio
1.47
Past 5Y EPS Growth
17.46%
This Y EPS Growth
12.12%
Next Y EPS Growth
(17.24%)
Next 5Y EPS Growth
(6.35%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
3.63%
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 39.71 51.72 63.81 63.98
Receivables 3.01 11.97 51.35 46.99
Inventory — — — —
Other — — — —
45.54 68.26 136.12 116.69
2023 2024 2025 Q'26
Payables 1.58 6.96 21.50 16.97
ST’ Debt — — — —
Other 3.80 4.06 1.38 2.69
13.72 90.88 86.75 73.11
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 39.23 27.19 — —
—
’25 20.88 39.73 72.41 104.24
237.26
’24 2.18 6.40 4.93 15.19
28.70
’23 0.68 1.36 2.10 3.25
7.38
’22 0.09 — — 0.02
0.11
’21 0.51 0.11 0.20 0.07
0.89
’20 2.90 0.52 0.27 0.36
4.05
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (2.05) 2.78 — —
—
’25 (9.60) (15.94) 2.60 30.66
7.71
’24 (21.19) (12.03) (4.20) (7.34)
(44.76)
’23 (24.46) (17.47) (15.00) (13.52)
(70.45)
’22 (25.11) (25.90) (14.61) (29.15)
(94.78)
’21 (16.59) (13.16) (14.27) (15.81)
(59.83)
’20 (3.21) (0.52) (9.25) (10.77)
(23.75)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (2.50) 2.75 — —
—
’25 (9.73) (15.84) 2.48 30.66
7.57
’24 (21.32) (12.40) (4.21) (7.39)
(45.32)
’23 (25.70) (17.92) (15.16) (13.42)
(72.20)
’22 (26.46) (28.22) (16.64) (33.05)
(104.38)
’21 (17.21) (15.36) (15.59) (16.83)
(64.99)
’20 (3.21) (0.53) (9.56) (11.67)
(24.97)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.02 (0.06) — —
—
’25 (0.07) (0.07) (0.04) 0.24
0.07
’24 (0.14) (0.09) (0.06) (0.05)
(0.33)
’23 (0.19) (0.16) (0.11) (0.12)
(0.57)
’22 (0.20) (0.23) (0.23) (0.18)
(0.84)
’21 (0.14) (0.13) (0.14) (0.17)
(0.58)
’20 (0.02) (0.12) (0.08) (0.13)
(0.36)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ 0.73 0.53 0.52 0.26 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 6.80 1.59 1.54 0.98 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 164 109 105 65 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.07 0.27 3.65 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.11 7.38 28.70 237.26 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (107.69) (82.20) (66.69) 16.80 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (100,645.79%) (1,114.03%) (232.36%) 7.08% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (107.76) (82.46) (66.95) 16.33 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.64 7.97 8.09 8.30 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.05 0.14 1.03 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.84) (0.57) (0.33) 0.07 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.74) (0.49) (0.22) 0.03 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.08) (0.01) 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.82) (0.50) (0.22) 0.03 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.87 0.40 0.29 0.38 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 127.68 144.82 202.14 230.27 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 5.83 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 315.02 11.97 4.65 0.34 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.09 1.53 2.26 0.92 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 135.77 10.17 3.77 0.18 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.50) (1.04) (2.39) 5.71 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (94.78) (70.45) (44.76) 7.71 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.60) (1.75) (0.55) (0.14) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (104.38) (72.20) (45.32) 7.57 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 81.53 31.81 (22.62) 49.37 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 27.42 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (68.30) (39.71) (51.72) (63.81) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 110.60 57.81 58.93 87.80 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (57.47%) (67.13%) (51.85%) 9.26% ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (169.30%) (287.93%) (575.30%) 47.09% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (72.29%) (97.94%) (114.71%) 22.26% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Vaxart, Inc. (VXRT) trades at deeply depressed levels near $0.60, down over 90% from 2021 peaks, yet screams undervaluation as an oral vaccine pioneer disrupting a $50B+ market. Revenue has exploded from $7.4M in 2023 to $28.7M in 2024 (+289% YoY), driven by norovirus pipeline progress and BARDA funding, with analyst forecasts projecting a staggering $202.7M in 2025 (606% surge). Fundamentals show resilience: per-employee revenue at $273K (up 302%), 100% gross margins, and EV/Sales compressing to 0.67 by 2025, contrasting with persistent cash burn easing toward breakeven.

Insider conviction is sky-high, with CEO and directors scooping 300K+ shares in 2025 at $0.49 averages—no sells amid troughs—aligning with unanimous analyst targets implying 600% upside from current levels. Losses narrowed 38% to -$66.9M in 2024, ROE projected to flip to +131% in 2025, and share dilution stabilizing at 240M. Catalysts like Phase 3 norovirus data and COVID boosters loom, offsetting risks such as a puzzling 2027 revenue cliff.

This microcap’s revenue inflection, efficiency gains, and bullish signals position it for multi-bagger potential—read the full analysis for the quantitative deep dive on correlations, projections, and asymmetry.

Read full commentary →

VAXART, INC. (VXRT) Latest News

News by impact score

Fine-tune

15 Sep

3 www.marketbeat.com, 2:02 AM
Vaxart presented its oral vaccine platform and COVID trial progress at the H.C. Wainwright Conference. Conference highlights on oral vaccine platform and COVID trials point to moderate effects on product development and sentiment.

26 Aug

3 , 4:07 PM
Vaxart obtains European patent for proprietary norovirus vaccine technology, expanding its intellectual property portfolio. Patent grant strengthens norovirus vaccine IP protection without altering core development trajectory.

10 Aug

4 transcript , 9:07 PM
Vaxart Inc's Q2 2026 earnings call highlighted progress on its oral COVID vaccine with positive early signals and provided updates on the company's cash position. Positive data on oral COVID vaccine directly advances core pipeline and could shift company trajectory.

9 Aug

3 transcript www.marketbeat.com, 4:03 PM
Vaxart reported Q2 results and pipeline updates during its earnings call, covering financials, oral vaccine candidates, and operational outlook. Quarterly earnings call supplies routine financial and pipeline details with moderate short-term market relevance.

7 Aug

3 transcript app.moby.co, 8:30 AM
Vaxart, Inc. discussed its Q2 2026 financial results and business updates during the earnings call. Quarterly earnings calls typically provide financial metrics and outlook that moderately influence near-term stock performance.

6 Aug

3 , 4:05 PM
Vaxart provides business update and reports second quarter 2026 financial results. Quarterly financial results and business updates can influence investor sentiment and stock performance for Vaxart.

6 Jul

3 , 4:01 PM
Vaxart reported topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b trial for the oral pill COVID-19 vaccine. Phase 2b safety data advances oral COVID-19 vaccine program without altering near-term trajectory.

7 May

3 GlobeNewswire, 4:05 PM
Vaxart, Inc. (VXRT) provided a business update and reported first quarter 2026 financial results. Quarterly financial results and business updates typically have moderate impact on financial performance and investor sentiment.

17 Apr

3 GlobeNewswire, 8:30 AM
Vaxart, Inc. (VXRT) announced a share purchase agreement with Lincoln Park Capital for up to $25 million in common stock purchases at the company's discretion. Securing up to $25 million via an equity line provides needed liquidity for operations but involves share dilution without transforming core prospects.

13 Mar

4 www.marketbeat.com, 12:07 AM
Vaxart, Inc. (VXRT) released highlights from its Q4 earnings call, detailing financial results, pipeline updates, and strategic outlook. Q4 earnings call highlights cover financial performance and pipeline developments that could significantly influence VXRT's market trajectory and investor sentiment.

3 app.moby.co, 8:30 AM
Vaxart, Inc. (VXRT) released Q4 2025 earnings call summary covering financial results, operational updates, clinical pipeline progress, and future outlook. Q4 2025 earnings summary reveals financial performance and pipeline developments with moderate influence on investor sentiment and trajectory.

12 Mar

4 GuruFocus.com, 11:08 PM
Vaxart Inc (VXRT) Q4 2025 earnings call highlighted a revenue surge and new strategic partnerships boosting growth prospects. Revenue surge strengthens finances and strategic partnerships expand pipeline, significantly impacting trajectory.

3 GlobeNewswire, 4:05 PM
Vaxart, Inc. (VXRT) provided a business update and reported full year 2025 financial results. Business update and full year 2025 financial results directly influence financial performance and investor assessment of the company's trajectory.

27 Jan

4 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 4:07 PM
Vaxart, Inc. (VXRT) has released new data from its oral norovirus vaccine candidate, focusing on its efficacy in breastfeeding women. The study, published in npj Vaccines, highlights the potential of the vaccine to elicit immune responses in this demographic, which is crucial for protecting infants. The findings may enhance Vaxart's position in the vaccine market, particularly in addressing norovirus, a significant cause of gastroenteritis. Investors are closely monitoring these developments as they could influence the company's future prospects. The new data on the oral norovirus vaccine candidate could significantly impact Vaxart's market position and investor sentiment.

18 Jan

3 www.marketbeat.com, 9:40 AM
VAXART, INC. (VXRT) is highlighted among three penny stocks that investors might reconsider despite previous reluctance. The company is involved in developing oral vaccines, which could position it favorably in the biotech sector. Recent developments and market trends suggest potential for growth, attracting attention from investors looking for undervalued opportunities. However, the inherent risks associated with penny stocks remain a concern, emphasizing the need for careful evaluation before investment. VAXART's developments in oral vaccines may moderately influence its market position and financial performance.

15 Jan

4 GlobeNewswire, 8:00 AM
Vaxart, Inc. has published positive data regarding its oral bivalent norovirus vaccine candidate, demonstrating safety and immunogenicity in lactating women and their infants. The study results indicate that the vaccine could provide protection against norovirus, which is a significant cause of gastroenteritis. This development is expected to enhance Vaxart's position in the vaccine market, particularly for maternal and infant health. The positive data from the study could significantly impact Vaxart's future performance and market positioning in the vaccine sector.

14 Nov

4 GuruFocus.com, 12:01 AM
Vaxart Inc (VXRT) reported significant revenue growth in Q3 2025, driven by a strategic partnership that enhances its market position. The earnings call highlighted key developments in product innovation and future prospects, indicating a positive trajectory for the company. The strategic partnership and revenue surge are likely to significantly impact Vaxart's future performance and investor sentiment.

13 Nov

3 GlobeNewswire, 4:05 PM
Vaxart, Inc. provided a business update alongside its financial results for the third quarter of 2025. The company reported progress in its oral vaccine development programs and highlighted key partnerships that are expected to enhance its market position. Financial results showed a modest increase in revenue compared to the previous quarter, reflecting ongoing investments in research and development. Vaxart remains focused on advancing its pipeline and addressing market needs in the vaccine sector. The developments in vaccine programs and partnerships may moderately influence Vaxart's financial performance and competitive positioning.

7 Nov

4 GlobeNewswireQuartzAssociated Press FinanceDetroit Free PressTheStreetAFPMT NewswiresMoney Digest, 4:05 PM
VAXART, INC. (VXRT) has received a notification from the Nasdaq Stock Market regarding the potential delisting of its securities due to failure to meet the minimum bid price requirement. The company has a 180-day grace period to regain compliance by achieving a minimum closing bid price of $1.00 for at least ten consecutive trading days. If VAXART fails to meet this requirement, it may face delisting, which could significantly impact its market presence and investor confidence. Failure to comply with Nasdaq's listing requirements could lead to delisting, significantly affecting investor sentiment and the company's market performance.

5 Nov

4 PR Newswire, 4:00 PM
Dynavax Technologies has entered into an exclusive license agreement with Vaxart, Inc. for its novel oral COVID-19 vaccine program. This collaboration aims to leverage Vaxart's innovative oral vaccine platform, which could enhance vaccine accessibility and distribution. The agreement is expected to accelerate the development and commercialization of the oral vaccine, potentially addressing ongoing public health needs related to COVID-19. The exclusive license agreement represents a significant strategic move that could enhance Vaxart's market position and product offerings in the competitive vaccine landscape.

8 Oct

4 GlobeNewswire, 8:00 AM
Vaxart, Inc. will present its oral pill vaccine candidates for norovirus and COVID-19 at the World Vaccine Congress Europe 2025. The company aims to highlight its innovative approach to vaccine development, focusing on oral delivery methods that could enhance patient compliance and accessibility. The showcase of oral vaccine candidates at a prominent conference could significantly influence Vaxart's strategic positioning and investor sentiment.

18 Sep

3 , 9:00 AM
Vaxart, Inc. stockholders have expressed concerns regarding the company's recent governance announcements, citing inadequate measures and a lack of transparency. Investors are worried that these governance issues could negatively impact the company's future performance and overall market confidence. The shareholders are calling for more accountability and better management practices to ensure the company's strategic direction aligns with shareholder interests. Governance concerns may moderately influence investor sentiment and operational aspects, but are not expected to drastically alter the company's trajectory.

17 Sep

3 , 4:05 PM
Vaxart, Inc. has appointed W. Mark Watson as the Lead Independent Director of its Board of Directors. Watson brings extensive experience in corporate governance and strategic leadership, having served in various executive roles across multiple companies. His appointment is expected to enhance the board's oversight and strategic direction as Vaxart continues to advance its oral vaccine platform and other initiatives. The appointment of a seasoned director may positively influence Vaxart's strategic direction and governance, but its immediate impact on financial performance is expected to be limited.

10 Sep

4 GlobeNewswire, 4:54 PM
Vaxart, Inc. reported additional Phase 1 data that supports the potential efficacy of its second-generation oral pill vaccine candidate for norovirus. The data indicates promising immune responses and safety profiles, bolstering the company's position in the vaccine market. This development is part of Vaxart's ongoing efforts to advance its oral vaccine platform, which aims to provide a more effective and convenient solution for norovirus prevention. The new Phase 1 data could significantly enhance Vaxart's competitive positioning and investor sentiment regarding its vaccine development.

3 , 9:00 AM
Vaxart, Inc. stockholders have expressed strong disapproval of the board's decision to adjourn the vote on a proposed reverse stock split during a special meeting. Investors are concerned that this delay could negatively impact the company's stock performance and overall market perception. The reverse stock split is seen as a necessary step to improve the stock's marketability and attract institutional investors. Shareholders are urging the board to reconsider and move forward with the vote to stabilize the company's financial standing. The adjournment of the reverse stock split vote may moderately influence investor sentiment and the company's market performance.

2 Sep

3 , 4:30 PM
Vaxart, Inc. announced the retirement of Chairman Michael J. Finney, Ph.D., from its Board of Directors. Finney has served as chairman since 2018 and has been instrumental in guiding the company's strategic direction. His departure marks a significant change in the leadership structure as Vaxart continues to develop its oral vaccine platform and pursue growth opportunities in the biotechnology sector. The retirement of a key board member may influence company strategy and investor sentiment but is not expected to drastically alter Vaxart's overall trajectory.

3 , 9:00 AM
Vaxart stockholders are expressing concern over a proposed reverse stock split and are urging fellow investors to vote against it. They are demanding accountability from the board, suggesting that the split could negatively impact shareholder value and the company's future. The stockholders believe that the board's actions warrant scrutiny and that the reverse split may not be in the best interest of the company or its investors. The proposed reverse stock split could moderately influence investor sentiment and the company's market performance.

29 Aug

3 GlobeNewswire, 8:00 AM
Vaxart, Inc. has received an extension from Nasdaq to regain compliance with its listing requirements. The company was previously at risk of being delisted due to its stock price falling below the minimum threshold. The extension allows Vaxart additional time to meet the necessary criteria and maintain its listing on the exchange. The extension provides Vaxart with a crucial opportunity to stabilize its stock price and avoid delisting, which could influence investor sentiment and operational focus.

21 Aug

3 , 9:30 AM
Vaxart, Inc. stockholders are expressing strong opposition to the company's recent decision to implement a reverse stock split. Concerned investors are uniting to defend their rights and challenge the move, which they believe could negatively impact shareholder value and market perception. The dissenting shareholders are advocating for transparency and better communication from the company's management regarding the rationale behind the split. The reverse stock split could moderately influence investor sentiment and stock performance, but its overall impact on the company's trajectory remains uncertain.

13 Aug

3 Zacks, 5:25 PM
VAXART, INC. (VXRT) reported a loss for Q2 but exceeded revenue estimates. The company's financial performance showed resilience despite challenges, indicating potential for future growth. Investors reacted positively to the revenue beat, suggesting confidence in VAXART's strategic direction. Exceeding revenue estimates may positively influence investor sentiment and financial performance, but the loss indicates ongoing challenges.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us